title: Antiatherogenic property of triterpenoids-enriched extract from the aerial parts of Salvia miltiorrhiza.
abstract: This study investigated the antiatherogenic activity and the chemical constituents of a triterpenoids-enriched extract from the aerial parts of Salvia miltiorrhiza Bunge. The extract displayed a significant, dose-responsive antiatherogenic effect on LDLR(-/-) mice after a 24-week application in a daily dose 50, 100, 200, 1000 mg/kg, respectively. Pronounced systemic inflammation and cutaneous xanthomatosis inhibition effects of the extract, combined with hypocholesteremic and plaque stable properties, were shown in this study. At 200 mg/kg in the high dose treated group, the percent inhibitions of two inflammatory markers in serum, CRP and MCP-1, were 47.6 +/- 4.2% and 36.8 +/- 5.0%, and significant reductions in aortic atherosclerotic lesion areas were 62.3 +/- 3.9% (en face) and 77.8 +/- 3.1% (cross section) compared with the model group. No abnormal behavior or lethality were observed with the extract up to 1000 mg/kg. Fifteen triterpenoids were separated and identified from the extract. This study provided new evidence of the antiatherogenic property of S. miltiorrhiza correlated with triterpenoids by an antiinflammatory mechanism.
authors.affiliation: Department of Chinese Materia Medica Analysis, China Pharmaceutical University, Nanjing, P. R. China 210038.
authors.forename: Qin
authors.initials: Q
authors.lastname: Zhang
authors.forename: Zai
authors.initials: Z
authors.lastname: Chang
authors.forename: Jie
authors.initials: J
authors.lastname: Yang
authors.forename: Qiang
authors.initials: Q
authors.lastname: Wang
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000737:chemistry / Q000627:therapeutic use*; D001011:Aorta / Q000187:drug effects / Q000473:pathology; D050197:Atherosclerosis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D001522:Behavior, Animal / Q000187:drug effects; D002097:C-Reactive Protein / Q000032:analysis; D001892:Camphanes; D018932:Chemokine CCL2 / Q000097:blood; D004036:Diet, Atherogenic; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation; D004365:Drugs, Chinese Herbal / Q000737:chemistry / Q000627:therapeutic use*; D005260:Female; D000960:Hypolipidemic Agents / Q000737:chemistry / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008136:Longevity / Q000187:drug effects; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D053723:Panax notoginseng; D035261:Plant Components, Aerial / Q000737:chemistry; D027544:Salvia; D027561:Salvia miltiorrhiza; D012871:Skin Diseases / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D014315:Triterpenes / Q000032:analysis / Q000737:chemistry; D014973:Xanthomatosis / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology
chemical_list: D000893:Anti-Inflammatory Agents; D001892:Camphanes; C491768:Ccl2 protein, mouse; D018932:Chemokine CCL2; D004365:Drugs, Chinese Herbal; D000960:Hypolipidemic Agents; D008055:Lipids; D014315:Triterpenes; C000604051:danshen dripping pill; D002097:C-Reactive Protein